AI-Enabled Medical Devices: Moving from Innovation Approval to Post-Market Control
AI-enabled medical devices have moved from emerging technology to operational reality. The U.S. Food and Drug Administration now maintains a public list of AI-enabled medical devices authorized for marketing in the United States, and the list continues to expand across radiology, cardiovascular, diagnostics, surgical support, monitoring, and other categories. For device companies, the competitive question is no longer whether AI can be embedded in clinical workflows. It is whether AI can be governed, monitored, updated, and supported safely after commercialization.
That distinction matters. Authorization is a milestone, not the end of risk. AI-enabled devices can perform differently as data inputs, clinical workflows, patient populations, hardware environments, software dependencies, user behavior, and site-level practices change. Model drift, software updates, integration issues, training gaps, complaint signals, labeling questions, and cybersecurity exposure can all affect performance after launch. The operating model must therefore extend beyond approval and into disciplined post-market control.
AI-enabled medical devices do not create durable value simply because they are authorized. They create value when the company can monitor real-world performance, control model and software changes, connect field signals to CAPA, train users responsibly, and govern the device across its full product lifecycle.
The Regulatory Direction Is Clear: Lifecycle Control Matters
For CEOs and boards, this changes the definition of AI readiness. It is not enough to have an innovative algorithm, a clearance strategy, or a digital roadmap. The enterprise needs governance that connects regulatory, quality, clinical, engineering, software, cybersecurity, commercial, service, legal, and field feedback. The companies that scale AI responsibly will be those that manage it as a total product lifecycle obligation rather than a product feature.
FDA’s AI-enabled medical device list is intended to improve transparency for innovators, clinicians, and patients, while helping stakeholders understand the evolving device landscape. The agency also states that listed devices have met applicable premarket requirements, including review of safety and effectiveness. At the same time, FDA notes that the list is not comprehensive and will continue to be updated periodically.
The agency’s recent AI-related guidance activity points in the same direction. FDA’s August 2025 final guidance on predetermined change control plans for AI-enabled device software functions recommends that a plan describe planned modifications, the methodology to develop, validate, and implement those modifications, and an assessment of their impact. FDA’s January 2025 draft guidance on lifecycle management and marketing submissions emphasizes documentation and risk management across the total product life cycle.
The message for device leaders is practical: AI-enabled medical devices require change control that is faster than traditional hardware cycles but disciplined enough to protect safety, effectiveness, and trust. The organization must know what can be changed, who can approve it, how it will be validated, how it will be monitored, how customers will be notified, and how issues will be escalated when real-world performance does not match expectations.
Post-Market Risk Is Already Visible
The post-market evidence base is still developing, but the warning signs are real. A 2025 JAMA Health Forum study examined 950 FDA-cleared AI-enabled medical devices and found that 60 devices were associated with 182 recall events. The study reported that 43.4% of those recalls occurred within the first 12 months after clearance, and that lack of clinical validation was independently associated with recall risk.
Reuters’ 2026 investigation into AI in medical devices reported that FDA had authorized at least 1,357 AI-enabled medical devices and highlighted adverse-event concerns involving several categories. Reuters also noted that FDA device reports can be incomplete and are not designed to establish causality on their own. That nuance is important. The point is not that AI-enabled devices are inherently unsafe. The point is that AI introduces a different post-market control challenge than many organizations are built to manage.
A traditional device failure may often be traced to a component, assembly, manufacturing process, labeling issue, or user training gap. AI-enabled devices can add additional layers: data distribution shifts, software dependencies, algorithm performance in edge cases, site-specific workflow variation, update management, and human-machine interaction. These risks do not replace traditional quality-system responsibilities; they expand them.
AI Governance Must Become an Operating System
Many device companies have strong regulatory and quality functions. Many also have strong engineering and software teams. The challenge is that AI requires these capabilities to operate together at a higher cadence. A model update may have implications for regulatory commitments, validation evidence, labeling, cybersecurity, field training, customer communication, service scripts, complaint coding, and CAPA. If those functions are not connected by clear management routines, the company may move too slowly to improve the device or too quickly without adequate control.
Effective AI governance should answer several operating questions. What performance metrics are monitored after launch? What thresholds trigger review? How is real-world performance stratified by site, patient population, hardware, software version, user type, and workflow? How are complaints and adverse-event signals coded so AI-related patterns are visible? How are updates validated before release? How are sales and service teams trained to avoid overclaiming capability? How does the company decide when a model change is an improvement, a risk, or a regulatory event?
These questions cannot be left to technical teams alone. AI-enabled devices sit at the intersection of clinical promise, regulatory obligation, product reliability, commercial adoption, and reputation. That makes governance a leadership issue. CEOs should expect clear ownership, escalation paths, decision rights, and review cadence for AI-enabled products, especially when products are deployed across varied clinical environments.
The Commercial Model Must Keep Pace with the Technology
AI devices are often sold on speed, accuracy, workflow improvement, access, or clinical confidence. Those claims must be translated into a supportable commercial model. Hospitals and clinicians need to understand when the device should be used, what it can and cannot do, how outputs should be interpreted, what training is required, and how performance will be monitored. Overstating capability can create clinical, legal, and reputational exposure. Under-supporting adoption can reduce utilization and weaken the return on innovation.
This creates an operating requirement around launch excellence. Medical device companies should align product management, clinical education, field service, customer success, regulatory, quality, and commercial leadership before launch. Training materials, labeling, value messaging, post-market surveillance, software-release communication, and complaint pathways should reinforce each other. The product cannot be managed as a static clearance asset when the customer experience is dynamic.
For companies with installed bases, the complexity is even greater. AI functionality may be added through software updates to devices already in the field. That creates questions around version control, customer opt-in, system compatibility, service burden, and customer communication. The operating model must be able to manage variation in the field without losing control of performance.
From Model Monitoring to CAPA
Post-market control depends on the company’s ability to convert real-world signals into decisions. Model performance, software defects, user confusion, complaint patterns, service tickets, integration failures, cybersecurity concerns, and adverse-event reports should not sit in disconnected systems. They should feed an integrated review process that can separate isolated noise from emerging risk.
This is where AI-enabled products can expose weaknesses in legacy operating models. A complaint may appear to be a training issue, but deeper review may reveal workflow mismatch, labeling ambiguity, model performance variation, or an update that changed user behavior. A service issue may appear technical, but the root cause may be poor site readiness, version-control breakdown, or inconsistent handoff between product management and field teams. If those signals are not analyzed together, the company may close the issue without solving the problem.
CAPA should therefore be connected directly to AI governance. The organization needs a way to determine when an AI-related signal requires investigation, when it requires customer communication, when it requires retraining or software change, and when it requires regulatory review. The point is not to slow innovation. The point is to ensure that learning from real-world use improves the device without creating unmanaged risk.
Board-Level Controls for AI-Enabled Growth
Boards do not need to manage algorithm design, but they do need confidence that AI-enabled devices are governed with the same seriousness as other enterprise risks. That requires management to provide more than innovation updates. Leaders should be able to show how AI product risk is identified, how performance is monitored, how model or software changes are controlled, how customer-facing claims are managed, and how issues are escalated.
This is particularly important as AI functionality becomes embedded in broader platforms rather than sold as a standalone tool. A single device may combine hardware, software, cloud connectivity, user interface design, data management, cybersecurity, and clinical workflow integration. A weakness in any part of that system can affect adoption or trust. Board-level oversight should therefore focus on whether the organization has clear ownership across the full system.
AI can accelerate growth, but only if the company can scale it in a way that customers, clinicians, regulators, and investors trust. That trust is built through evidence, transparency, disciplined change control, and reliable post-market response. The leadership question is not simply, ‘How many AI products are in the pipeline?’ It is, ‘Can the enterprise control and improve those products after they reach real clinical environments?’
The Brooks International Perspective
AI-enabled devices will reward companies that can combine innovation speed with operating discipline. Brooks International’s perspective is that the biggest risk is not the algorithm in isolation. The bigger risk is the gap between the innovation roadmap and the management system required to control the device after launch.
Closing that gap requires a defined operating architecture: governance forums, decision rights, validation routines, field-feedback loops, issue escalation, CAPA integration, release management, customer training, and performance reporting that reaches senior leadership. When these routines are clear, AI can be improved and scaled without creating unmanaged risk. When they are weak, the company may find itself reacting to customer complaints, regulatory scrutiny, service issues, or adoption problems after value has already been lost.
The next phase of medtech AI will not be judged only by the number of devices authorized. It will be judged by whether those devices perform reliably in the real world, improve clinical and operating outcomes, and maintain trust over time. For medical device leaders, post-market control is not a compliance afterthought. It is the operating foundation for AI-driven growth.
What Medical Device Leaders Should Be Asking Now
The leadership agenda should focus on whether AI-enabled products are governed across the full lifecycle, from submission strategy and launch through real-world monitoring, change control, customer support, and corrective action.
• Who owns post-market performance of AI-enabled devices after authorization, and how are issues escalated to senior leadership?
• What real-world performance metrics are monitored by site, user type, patient population, software version, and workflow environment?
• How are model updates, software releases, labeling changes, cybersecurity concerns, and customer communication governed together?
• Can complaint, service, and adverse-event signals reveal AI-related patterns quickly enough to support corrective action?
• Does the commercial organization understand the approved claims, limitations, training requirements, and adoption risks of AI-enabled products?
• Are real-world learning loops improving product decisions without creating uncontrolled change or claim-expansion risk?
The Leadership Imperative
AI-enabled medical devices will become more common, more connected, and more embedded in clinical workflows. That makes lifecycle governance a growth requirement, not only a regulatory requirement.
The winners will not simply be the companies with the most algorithms on the market. They will be the companies that can prove those products perform reliably, manage change responsibly, and respond to field signals before trust is damaged.
For medical device leaders, the mandate is clear: build AI governance into the operating model now, before post-market complexity outpaces the management system.
